Loading…
Apollomics, Inc. is projected to rise to $23.76 by 2027, a +38% move from its current price of $17.25. APLM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $15.98 | $17.23 | $18.57 | -0.12% |
| Aug 6 | $15.48 | $17.21 | $19.13 | -0.23% |
| Aug 7 | $15.09 | $17.19 | $19.57 | -0.35% |
| Aug 8 | $14.78 | $17.17 | $19.94 | -0.46% |
| Aug 9 | $14.50 | $17.15 | $20.27 | -0.57% |
| Aug 10 | $14.26 | $17.13 | $20.58 | -0.69% |
| Aug 11 | $14.03 | $17.11 | $20.86 | -0.80% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.03 | $17.11 | $20.86 | -0.80% |
| Week 2 | $12.82 | $16.97 | $22.46 | -1.60% |
| Week 3 | $11.94 | $16.83 | $23.73 | -2.39% |
| Week 4 | $11.23 | $16.70 | $24.82 | -3.17% |
| Week 5 | $10.63 | $16.56 | $25.80 | -3.95% |
| Week 6 | $10.11 | $16.43 | $26.70 | -4.72% |
| Week 7 | $9.65 | $16.30 | $27.53 | -5.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its product portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Apollomics, Inc. (APLM) is a healthcare company with a current price of $18.52 and a market cap of $40.67M. It is ranked 4490 by market capitalization. The stock trades within a framework that suggests potential upside over the multi-year horizon, with a 2026 forecast near the current price and progressively higher averages and bullish sentiment from 2027 onward.
This includes a sequence of rising averages through 2050, reflecting expected price appreciation under the forecast.
A major floor 46.8% below — a decisive break under it would weaken the trend.
The nearest floor, 17.6% below — buyers have tended to step in here.
The nearest ceiling, 34.9% above — a clean break opens room to run.
A major ceiling 58.3% above — clearing it would confirm fresh momentum.
Key APLM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APLM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.66 | Sell | $17.63 | Sell |
| MA 10 | $18.15 | Sell | $17.99 | Sell |
| MA 20 | $18.38 | Sell | $18.18 | Sell |
| MA 50 | $17.08 | Buy | $17.57 | Sell |
| MA 100 | $16.40 | Buy | $17.09 | Buy |
| MA 200 | $17.72 | Sell | $16.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.60 | Neutral |
| Stoch RSI (14) | 16.97 | Buy |
| CCI (20) | -71.20 | Neutral |
| Williams %R (14) | -79.59 | Info |
| MACD (12,26,9) | -0.30 | Sell |
| ROC (12) | -10.14 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 20.41 | Neutral |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -0.86 | Sell |
| Ultimate (7,14,28) | 34.57 | Neutral |
| Momentum (10) | -1.27 | Sell |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 17.20 | Buy |
| ADX (14) | 10.09 | Neutral |
| ATR (14) | 0.94 | Info |
The 30-day technical picture is currently NEUTRAL. The RSI(14) is 50, and the stock sits between its key moving averages with the SMA50 at $16.40 and the SMA200 at $17.74. Near-term support is $13.70 and resistance is $23.27. Over the last 30 days, the price has moved within a range of $9.52 to $36.04, indicating notable volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.85 | $17.25 | $20.70 | 0% | Neutral | |
| $17.31 | $23.76 | $35.24 | +38% | Bullish | |
| $21.27 | $31.04 | $49.12 | +80% | Bullish | |
| $18.86 | $29.00 | $48.21 | +68% | Bullish | |
| $18.33 | $29.56 | $51.18 | +71% | Bullish | |
| $17.28 | $29.13 | $52.23 | +69% | Bullish | |
| $16.68 | $29.34 | $54.24 | +70% | Bullish | |
| $18.52 | $33.92 | $64.47 | +97% | Bullish | |
| $22.38 | $42.64 | $83.10 | +147% | Bullish | |
| $26.51 | $52.52 | $104.75 | +205% | Bullish | |
| $27.50 | $61.10 | $133.99 | +254% | Bullish | |
| $51.55 | $114.56 | $263.48 | +564% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $12.85 | $17.25 | $20.85 | +0.00% |
| September 2026 | $12.67 | $15.40 | $19.53 | -10.68% |
| October 2026 | $12.60 | $15.52 | $20.09 | +0.78% |
| November 2026 | $13.05 | $16.27 | $21.39 | +4.78% |
| December 2026 | $12.32 | $15.52 | $20.70 | -4.61% |
Click any year to see its month-by-month APLM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The APLM price prediction for 2026 points to an average of $17.25 (low $12.85, high $20.70) — a potential gain of 0% on today's $17.25. A consolidation phase looks the most probable path here.
In 2027, APLM is projected to trade between $17.31 and $35.24, averaging $23.76 — a potential gain of +38% from today's $17.25. That is up +38% on the projected 2026 average. Momentum favours further upside here.
Apollomics, Inc.'s 2028 outlook centres on $31.04, within a $21.27 to $49.12 range. That is up +31% on the projected 2027 average. That marks a +80% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, APLM could reach as high as $48.21, with a base case around $29.00 and support toward $18.86 — roughly +68% from $17.25. Momentum favours further upside here.
Expect APLM to range from $18.33 to $51.18 through 2030. The $29.56 average target implies a +71% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The APLM price prediction for 2031 points to an average of $29.13 (low $17.28, high $52.23) — a potential gain of +69% on today's $17.25. Momentum favours further upside here.
In 2032, APLM is projected to trade between $16.68 and $54.24, averaging $29.34 — a potential gain of +70% from today's $17.25. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Apollomics, Inc.'s 2033 outlook centres on $33.92, within a $18.52 to $64.47 range. That is up +16% on the projected 2032 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2034, APLM could reach as high as $83.10, with a base case around $42.64 and support toward $22.38 — roughly +147% from $17.25. Buyers look set to stay in control over this stretch.
Expect APLM to range from $26.51 to $104.75 through 2035. The $52.52 average target implies a +205% move from current prices. That is up +23% on the projected 2034 average. Momentum favours further upside here.
The APLM price prediction for 2040 points to an average of $61.10 (low $27.50, high $133.99) — a potential gain of +254% on today's $17.25. Buyers look set to stay in control over this stretch.
In 2050, APLM is projected to trade between $51.55 and $263.48, averaging $114.56 — a potential gain of +564% from today's $17.25. That is up +87% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in APLM today (≈ 57.987823 APLM) could be worth
$6,642.94
+$5,642.94 (+564%) by 2050 · US Dollar
Based on the average projected APLM price of $114.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APLMwould be worth at today's price.
$1,000 invested in APLM on Jul 31, 2025 (≈ 171.821301 APLM) would be worth
$2,963.06
+$1,963.06 (+196.3%) today · 2.96× · US Dollar
Based on a APLM entry price of $5.82 vs. today's $17.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.21 | $947.01 | -5.3% |
| 1 month ago | $20.16 | $855.41 | -14.5% |
| 3 months ago | $16.22 | $1,063.19 | +6.3% |
| 6 months ago | $21.77 | $792.15 | -20.8% |
| 1 year ago | $5.82 | $2,963.06 | +196.3% |
| All time (4.7y) ago | $990 | $17.42 | -98.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APLM forecast.
Our base-case forecast reaches $34.00 around 2034.
Implied market cap at $34.00: $74.67M
The multi-year forecast shows an upside trajectory with bullish sentiment persisting from 2027 through 2050. In 2027 the average price is forecast at $26.65 with a 43.9% ROI. By 2028 the average rises to $33.39 (80.3% ROI), and the momentum continues into 2029 with an average of $29.64 (60.1% ROI).
In 2030 the average is $32.55 (75.8% ROI), and 2031–2032 stay in a bullish path with 2031 at $31.55 (70.4% ROI) and 2032 at $29.84 (61.1% ROI). The forecast continues to 2033–2035 with strong upside, including 2033 average $37.48 (102.4% ROI), 2034 $45.54 (145.9% ROI), and 2035 $54.75 (195.6% ROI). The long-range outlook stretches to 2040 (average $63.71, 244% ROI) and 2050 (average $118.72, 541% ROI).
These figures imply meaningful appreciation as the years progress, but they are not guarantees. The sentiment is bullish across 2027–2050, following a neutral stance in 2026.
Tap a question to reveal the answer.
Avg $32.55; min $20.14; max $56.46; ROI 75.8%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with yearly averages rising (2027 avg $26.65; 2028 avg $33.39; 2030 avg $32.55; 2040 avg $63.71; 2050 avg $118.72). Notable ROIs include 43.9% in 2027, 80.3% in 2028, 244% in 2040, and 541% in 2050.
Yes. The forecast includes a 2033 max of $71.32 and a 2034 max of $88.86, with a 2035 max of $109.32, indicating the potential to exceed $70 by the mid-2030s.
Current price is $18.52 and market cap is $40.67M; the rank is 4490.
The 30-day range spans $9.52 to $36.04. RSI(14) is 50, with SMA50 at $16.40 and SMA200 at $17.74. Near-term support is $13.70 and resistance is $23.27.
Apollomics, Inc. Community Discussion
0Share your Apollomics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.